Intra Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric, neurologic, and other disorders, leveraging Nobel Prize-winning research and a diverse pipeline of investigational compounds.
Company Overview
Intra Cellular Therapies is dedicated to developing treatments for neuropsychiatric, neurologic, and other disorders. The company's mission is to deliver innovative treatments to improve the lives of individuals with these conditions. Located at 430 East 29th Street, Suite 900, New York, NY 10016, the company leverages Nobel Prize-winning research by Dr. Paul Greengard to formulate its medical advancements.
Product Pipeline
The company's pipeline includes diverse investigational compounds in various stages of drug development. Key platforms include lumateperone, ITI-1284-ODT-SL, phosphodiesterase 1 (PDE1) inhibitors, ITI-333, and the ITI-1500 series. ITI-1284 is a deuterated form of lumateperone created as an oral disintegrating tablet for sublingual administration. ITI-333 acts as a partial agonist at mu-opioid (MOP) receptors and an antagonist at serotonin 5-HT2A receptors, while the ITI-1500 series focuses on non-hallucinogenic psychedelics with ITI-1549 as the lead candidate.
Core Technologies
Intra Cellular Therapies employs a drug discovery platform known as CNSProfile™. This platform assists in developing treatments targeting central nervous system disorders. Additionally, the company explores the potential of phosphodiesterase type 1 (PDE1) inhibitors for treating both CNS and non-CNS disorders, with the aim of restoring normal function in disease states.
Trademark and Key Products
The company holds a registered trademark for CAPLYTA, one of its significant product lines. The ITI-1284-ODT-SL formulation, ITI-333 novel compound, and ITI-1500 series' non-hallucinogenic psychedelics such as ITI-1549 are some of the pivotal products in the company's portfolio aimed at treating neuropsychiatric and neurologic disorders.
Research and Development Focus
Intra Cellular Therapies focuses on developing treatments for schizophrenia, bipolar depression, major depressive disorder, behavioral disturbances associated with Alzheimer’s disease, and Parkinson’s disease. The company's innovative approach is grounded in Nobel Prize-winning research, aiming to bring new therapies to market to address these complex conditions.